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For a number of years, there has been increasing interest in the concept of directly targeting intestinal
phosphate transport to control hyperphosphatemia in chronic kidney disease. However, progress has been
slow due to the paucity of information on the mechanisms involved in intestinal phosphate absorption. This
editorial highlights the most recent developments in our understanding of this process and the role of the
intestine in the maintenance of phosphate balance.
Recent findings
Recent studies in NaPi-IIb knockout mice have confirmed that this transport protein plays a significant role in
intestinal phosphate absorption and is critical in the proposed feed-forward mechanism between the small
intestine and kidney, which helps to maintain normal phosphate balance and steady-state plasma phosphate
concentrations. In addition, renal failure-induced hyperphosphatemia is attenuated in NaPi-IIb knockout mice,
confirming that NaPi-IIb is a suitable target in the prevention and treatment of hyperphosphatemia.
Summary
Recent findings suggest that consumption of processed foods containing phosphate preservatives may lead
to excessive phosphate exposure (if not overload), toxicity, and cardiovascular disease in the general
population, as well as in patients with declining renal function. Therefore, establishing more effective ways
of targeting the intestine to limit dietary phosphate absorption could have wide-reaching health benefits.
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ance and altered homeostasis can result in calcium
phosphate deposition in blood vessels, leading to
stiffening of arteries and myocardial dysfunction,
and an increased risk of cardiovascular disease. This
form of ‘phosphate toxicity’ is widely recognized to
occur in patients with chronic kidney disease (CKD),
but it has also been hypothesized that consumption
of food high in phosphate can cause similar cardio-
vascular changes in healthy individuals. Therefore, a
better understanding of what controls phosphate
balance has potentially wide-reaching benefits,
particularly for patients with CKD.
Although there have been significant advances
in our understanding of the hormonal changes that
regulate phosphate balance and renal phosphate
handling, our knowledge of the processes control-
ling intestinal phosphate absorption is still limited.
This article reviews the recent literature on the role
of the intestine in normal phosphate homeostasis
and how this may be altered in CKD. It also
highlights some new evidence for the concept ofilliams & Wilkins. Unau
Health | Lippincott Williams & Wilkphosphate-containing additives used to flavor and
preserve food.THE ROLE OF PHOSPHATE IN VASCULAR
CALCIFICATION IN CHRONIC KIDNEY
DISEASE
Hyperphosphatemia is a serious consequence of late
stage CKD [1], leading to increased cardiovascularthorized reproduction of this article is prohibited.
ins www.co-nephrolhypertens.com
CKEY POINTS
 NaPi-IIb plays an important role in phosphate
homeostasis, particularly during growth
and development.
 Generation of NaPi-IIb knockout mice has confirmed
that NaPi-IIb protein is a potential target to prevent and
treat hyperphosphatemia in CKD.
 The processes of intestinal phosphate transport could
also be targeted to reduce the impact of postprandial
fluctuations in serum phosphate (phosphate toxicity) in
the general population, as well as in patients
with CKD.
Renal pathophysiologymorbidity and mortality, particularly in patients on
dialysis [2]. Normalization of serum phosphate
levels has, therefore, been a clinical target in
patients with CKD. However, as serum phosphate
concentration represents a dynamic balance
between intestinal phosphate absorption, renal
phosphate excretion, and exchange between bone
and extracellular storage pools, measurement of
serum phosphate may not always be indicative of
phosphate imbalance or total body phosphate load.
Indeed, a recent short-term study of calcium and
phosphate balance in patients with stage 3/4 CKD
found no evidence for a significant net positive
balance in phosphate (or calcium) [3]. That serum
phosphate levels alone are not a good index of
altered phosphate homeostasis is also highlighted
by the finding that vascular calcification can occur
in early CKD when phosphate levels are normal or
near normal [4], and by the finding that fibroblast
growth factor 23 (FGF-23) [5] and Klotho [6] may
change even earlier in CKD, possibly independent of
phosphate, and are potential predictors of vascular
calcification and mortality in their own right. In
addition, a recent study has demonstrated that even
when serum phosphate levels are within the normal
range, high serum FGF-23 concentrations combined
with a low urinary fractional phosphate excretion
are strongly associated with higher mortality and
cardiovascular events, and that simultaneous
measurement of these two parameters may also be
predictors of patient outcome [7].
Current strategies for the treatment of hyper-
phosphatemia in dialysis patients include dietary
phosphate restriction and oral phosphate binders,
although these treatments, if used aggressively, can
lead to malnutrition, adverse gastrointestinal
effects, and poor compliance with all medications,
particularly in the elderly. Phosphate binders are
effective at lowering serum phosphate levels, but
they have recognized side-effects depending onopyright © Lippincott Williams & Wilkins. Unautho
482 www.co-nephrolhypertens.comtheir formulation, for example, aluminum toxicity
and hypercalcemia. Efficacy and longer-term safety
data on newer aluminum-free and calcium-free
binders are becoming available and show that com-
pounds such as sevelamer and lanthanum carbonate
offer equivalent phosphate-lowering capacity and
may reduce vascular calcification progression and
improve patient outcomes (for a recent comprehen-
sive review, see [8
&
]).
Recent studies comparing different phosphate
binders in patients with early and/or moderate CKD
have reported lower mortality rates [9,10] and
attenuated progression of secondary hyperparathy-
roidism, but increased progression of vascular cal-
cification [11]. These findings highlight the need
for more clinical trials before phosphate binders
can be recommended for routine use in early or
moderate CKD, but also demonstrate the need for
alternative strategies for preventing phosphate
imbalance. One such strategy under investigation
is the targeted inhibition of the NaPi-IIb trans-
porter; however, progress in this area has been
hampered by the fact that our understanding of
the control of intestinal phosphate transport in vivo
is still quite limited.THE EMERGING CONCEPT OF DIET-
INDUCED PHOSPHATE TOXICITY
There is now compelling evidence that phosphate is
a risk factor for cardiovascular events in individuals
with normal renal function [12,13] and that age-
related cardiovascular changes may be a con-
sequence of subtle changes in phosphate balance
[14,15]. Indeed, studies have shown that healthy
patients with serum phosphate more than 3.5mg/dl
(>1.13mmol/l) have a 55% higher risk of develop-
ing cardiovascular disease [16].
Dietary phosphate consumption can vary sig-
nificantly depending on food choices; ingestion of
processed food containing high levels of phosphate
preservatives may lead to supraphysiological post-
prandial spikes in blood phosphate levels and pose a
long-term cardiovascular risk [17]. Consistent with
this hypothesis is a recent study in healthy young
women demonstrating that ingestion of two differ-
ent phosphate salts commonly used as food addi-
tives resulted in significantly increased serum
phosphate levels for up to 10h, and that even after
20h phosphate remained elevated [18
&&
]. These
findings are particularly important for individuals
on low incomes, which includesmany patients with
CKD, who are more than twice as likely to have
hyperphosphatemia than those on higher incomes
[19]. This difference is attributed to the high intake
of cheaper processed food and is likely to pose arized reproduction of this article is prohibited.
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CKD patients in this population.SOURCES OF DIETARY PHOSPHATE
Phosphate is present in high amounts in animal
protein-based foods such as meat and fish, in dairy
products, whole grains, and nuts. However, changes
in the composition of our western diet have resulted
in a dramatic, and almost hidden, increase in con-
sumption of processed foods containing phosphate
additives to enhance flavor, improve color, and to
extend the shelf life of these products (see [20] for a
comprehensive list of common phosphate additives
used in food). A major concern is that the food
industry is not currently required to provide infor-
mation about naturally occurring or added phos-
phate levels in their food labeling; when this is
given, the phosphate content is often underesti-
mated or obscured by the complicated names of
the different additives [21]. In fact, additives may
increase the phosphate content of food by as much
as 70% [22]. Another complicating factor is that
inorganic phosphate from preservatives may have
much higher bioavailability, resulting in more than
90% absorption, compared with only 40–60% for
naturally occurring dietary phosphate [20].SODIUM-DEPENDENT VS. SODIUM-
INDEPENDENT INTESTINAL PHOSPHATE
ABSORPTION: INSIGHTS FROM NaPi-IIb
KNOCKOUT MICE
Early studies showed that dietary phosphate absorp-
tion occurs in the small intestine [23,24] and that
the underlying transport process could be resolved
into sodium-dependent and sodium-independent
components [25–27]. For a comprehensive over-
view of the older literature on phosphate transport
and its regulation, see [28–30]. The realization that
the gut is a potential target tissue for developing newCopyright © Lippincott Williams & Wilkins. Unau
Table 1. Age and partial or complete ablation of the NaP
controlling phosphate balance
4-week NaPi-I
Intestinal sodium-dependent phosphate transport # 50%
Urinary phosphate excretion #
NaPi-IIa protein expression "
NaPi-IIc protein expression "
Serum phosphate #
FGF-23 #
1,25 dihydroxyvitamin D3 "
FGF-23, fibroblast growth factor 23. Data from [29,32].
1062-4821  2013 Wolters Kluwer Health | Lippincott Williams & Wilktherapeutic strategies to control hyperphosphat-
emia in CKD has led to more detailed investigation
of the processes and regulation of intestinal phos-
phate transport. Targeted deletion of the NaPi-IIb
gene has been shown to result in developmental
arrest and fetal death [31,32], while conditional
tamoxifen-inducible NaPi-IIb/ knockout mice
[33] and heterozygote NaPi-IIbþ/ knockout mice
[31] have been generated to investigate the role of
this protein in intestinal phosphate transport and
phosphate homeostasis postnatally. Table 1 sum-
marizes the outcomes of studies using these mouse
models.
Complete ablation of the NaPi-IIb gene has
revealed that this protein accounts for approximately
90% of sodium-dependent phosphate transport
across themouse ileum [33].However, this study also
showed that even when this protein is maximally
induced by feeding a low phosphate diet, the trans-
porter accounted foronly approximately50%of total
phosphate absorption, confirming early findings
of a significant sodium-independent component of
intestinal phosphate transport [26,27]. Adenine-
induced CKD in NaPi-IIb/ knockout mice results
in only partial prevention of hyperphosphatemia;
the authors proposed that this might be a con-
sequenceof highpassive transport rates of phosphate
absorption caused by maintaining mice on a high
phosphate diet [34
&&
]. In keeping with this expla-
nation is the observation that treatment of CKD
NaPi-IIb/ knockout mice with sevelamer normal-
ized serum phosphate levels. Taken together, these
findings clearly demonstrate that both sodium-
dependent and sodium-independent phosphate
transport occur in the small intestine and that both
pathways can contribute to hyperphosphatemia in
advanced CKD. Although our understanding of the
role of NaPi-IIb in this process has increased through
the generation of NaPi-IIb/ knockout mice, future
studies are required to specifically investigate the
mechanism(s) of sodium-independent phosphatethorized reproduction of this article is prohibited.
i-IIb gene have different effects on parameters
Ibþ/ 20-week NaPi-IIbþ/ 10-week NaPi-IIb/
# 60% # 90%
# #
$ "
$ $
$ $
$ #
$ "
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CRenal pathophysiologytransport, as this route is also a potential therapeutic
target to limit hyperphosphatemia.
Reports to date suggest that the pathway
for sodium-independent phosphate transport is
unregulated [35–37]; however, it is unclear whether
transport occurs via a transcellular or paracellular
route. In this context, claudins and occludins are
known to provide a paracellular route for passive ion
flow, as well as providing cell adhesion between
epithelial cells [38]. These tight junction proteins
are regulated by signal transduction pathways and
provide selectivity for paracellular ion transport.
The finding that multiple isoforms of these proteins
exist, with particular expression profiles along the
gastrointestinal tract, suggests that they may have a
specific role in controlling transport and barrier
function in defined intestinal segments [38].
Whether tight junction proteins selectively influ-
ence paracellular phosphate transport has not been
investigated. Alternatively, an unidentified trans-
porter at the enterocyte brush border membrane
(BBM) may be responsible for transcellular phos-
phate transport. In this regard, it is of interest to
note the advancement in our understanding of the
pathways involved in intestinal glucose absorption.
Originally, the diffusive, sodium-independent com-
ponent of intestinal glucose transport was attributed
to paracellular transport [39]. However, it is now
recognized that this pathway accounts for only
1–2% of glucose flux during a meal, and that the
low affinity facilitative glucose transporter, GLUT2,
provides the pathway for transcellular glucose
absorption [40]. It is important to note that the
facilitative pathway for intestinal glucose transport
was overlooked in early in-vitro studies because of
the rapid internalization of the GLUT2 away from
the BBM during preparation of tissue for in-vitro
uptake studies [41]. Therefore, using in-vivo tech-
niques to examine the relevant contribution of
these pathways to phosphate absorption may be
more physiologically relevant.INTESTINAL TYPE III PHOSPHATE
TRANSPORTERS
Studies have suggested that the type III sodium-
dependent phosphate transporters, PiT1 and PiT2,
are also involved inmaintaining phosphate balance.
In the rat, PiT1 is expressedat theenterocyteBBMand
the regional expression mirrors that of NaPi-IIb [42].
In the mouse, PiT1 protein has been detected in
both the proximal and distal small intestine [31],
whereas so far PiT2 protein has been reported only
in the ileum [43]. Studies have shown residual
sodium-dependent phosphate transport in NaPi-
IIb/ knockout mice accounting for approximatelyopyright © Lippincott Williams & Wilkins. Unautho
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mediated or PiT2-mediated transport is unknown.
Further studies will be necessary to determine
whether these transporters make a significant con-
tribution to intestinal phosphate absorption.PHOSPHATE HOMEOSTASIS: INSIGHTS
FROM NaPi-IIb KNOCKOUT MICE
The heterozygote NaPi-IIbþ/ mouse has been used
to highlight the function of this transporter in
phosphate homeostasis during growth and develop-
ment. At 4 weeks of age, NaPi-IIbþ/ mice show
significant downregulation of NaPi-IIb mRNA and
protein levels, with impaired intestinal phosphate
transport and associated hypophosphatemia. Inter-
estingly, the reduction in NaPi-IIb expression and
function was also associated with decreased FGF-23
levels and activation of renal NaPi-IIa and NaPi-IIc
transporter expression; however, renal adaptation
was not sufficient to prevent hypophosphatemia
[31]. In contrast, at 20 weeks, the reduced urinary
phosphate excretion in NaPi-IIbþ/ mice was
sufficient to maintain normal serum phosphate
concentrations [31]. These findings support a
critical role for NaPi-IIb in intestinal phosphate
transport and phosphate homeostasis during onto-
genesis, and confirm previous observations that
sodium-dependent phosphate uptake and NaPi-IIb
protein expression are highest during weaning,
which reflects the higher phosphate requirement
for normal skeletal growth [44,45].
Studies using NaPi-IIb knockout mice also
highlight the possible role of NaPi-IIb in the pro-
posed feed-forward mechanism linking the small
intestine and kidney in maintaining phosphate
balance. Altered urinary phosphate excretion and
renal phosphate transporter expression are present
in both NaPi-IIbþ/ and NaPi-IIb/ knockout mice,
and are associated with decreased FGF-23 levels
[31,34
&&
]. It is currently unclear whether these
changes occur as a result of reduced intestinal phos-
phate transport or whether NaPi-IIb protein is part
of the machinery responsible for triggering hormo-
nal changes that influence phosphate balance. Of
interest is the fact that the transporters responsible
for the decrease in urinary phosphate excretion
appear to differ depending on age and type of knock-
out mouse model used (see Table 1). The fact that
NaPi-IIc is upregulated at 4 weeks in NaPi-IIbþ/
mice [31], but not at 10 weeks in NaPi-IIb/ mice
[33] is perhaps not surprising, as NaPi-IIc expression
and function in renal phosphate reabsorption has
been reported to be age-dependent [46]. However,
what is unexpected is that at 20 weeks, NaPi-IIbþ/
mice have persistent hypophosphaturia withoutrized reproduction of this article is prohibited.
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FGF-23 levels [31]. The changes observed in renal
phosphate transporter expression in mice with
NaPi-IIb deletion might explain the finding that
in human pulmonary alveolar microlithiasis, a dis-
order caused by inactivating mutations in NaPi-IIb,
patients do not exhibit significant changes in serum
phosphate concentrations [47], but do have
decreased FGF-23 levels and urinary phosphate
excretion [48].INTESTINAL PHOSPHATE TRANSPORT
AND PHOSPHATE HOMEOSTASIS IN
CHRONIC KIDNEY DISEASE
Our own research demonstrated that induction of
CKD in rats, using the 5/6 nephrectomy model, did
not alter intestinal phosphate transport, suggesting
that the gut might be a suitable therapeutic target
to prevent or reduce hyperphosphatemia [49]. A
similar finding has been made in the Han:SPRD
Cy/þ rat, a spontaneous model of renal cystic dis-
ease that develops CKD and mineral bone disorder.
Contrary to the authors’ interpretation, the data
show that jejunal phosphate flux in this model is
unchanged when compared with normal rats on no
binder treatment [50]. Moreover, studies in mice
with adenine-induced renal failure also show BBM
phosphate uptake is unchanged [31], and that there
is either no change [31] or a nonsignificant trend for
decreased NaPi-IIb protein levels following induc-
tion of CKD [34
&&
].
Recent mouse studies demonstrate for the first
time that NaPi-IIb deletion attenuates hyperphos-
phatemia in models of CKD, supporting NaPi-IIb as
a suitable treatment target for hyperphosphatemia
in CKD. However, it is worth noting that induction
of CKD in the two different mouse models of NaPi-
IIb deletion had varying effects on serum phosphate
levels. In the NaPi-IIbþ/ mouse, serum phosphate
levels in adenine-induced CKD did not change sig-
nificantly, whereas adenine-treated wild-type mice
developed hyperphosphatemia [31]. In contrast, in
the NaPi-IIb/ mouse there was only partial ameli-
oration of hyperphosphatemia in adenine-induced
CKD, and additional treatment with sevelamer was
required to prevent this and reduce FGF-23 levels
[34
&&
]. These inconsistencies have been attributed to
differences in dietary phosphate bioavailability
[34
&&
], but might also be due to inherent differences
between the knockout mice per se, or in the mode
and duration of adenine administration. Moreover,
in NaPi-IIb/ mice with CKD induced surgically,
rather than chemically, hyperphosphatemia is pre-
vented [34
&&
]. Another interesting observation in
adenine-treated NaPi-IIbþ/ mice was a decrease inCopyright © Lippincott Williams & Wilkins. Unau
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NaPi-IIb activity might also limit CKD progression;
however, this apparent renoprotection was not seen
in the NaPi-IIb/ mouse with adenine-induced or
surgically induced renal failure, even when serum
phosphate levels were normalized with binders
[34
&&
]. Collectively, these findings suggest that
development of inhibitors to directly target NaPi-
IIb-mediated phosphate transport may prove thera-
peutically useful for at least some patients withCKD.
However, it is envisaged that this treatment strategy
will require the additional use of phosphate binders
to effectively target both pathways of intestinal
phosphate absorption, particularly in patients on
dialysis. This combined approach might allow the
use of lower doses of phosphate binders (which
often cause significant gastrointestinal side-effects,
leading to reduced patient acceptance and toler-
ance), as well reduce the risk of calcium overload
when given as calcium carbonate [3], and it may
enhance patient well being and lead to improved
phosphate homeostasis.GUT–RENAL AXIS IN THE CONTROL OF
PHOSPHATE HOMEOSTASIS
In 2007, a feed-forward mechanism between the
small intestine and kidney was proposed in the
regulation of phosphate balance. Instillation of
phosphate into the duodenum released a putative
‘enteric phosphatonin’ that caused rapid renal
excretion of phosphate. Intravenous infusion of a
duodenal extract also evoked phosphaturia, demon-
strating that the intestine was the probable source of
this phosphatonin [51]. However, to date there has
been no further published information on the
mechanisms underlying this proposed entero-renal
reflex or the identity of the putative phosphatonin,
although it does not seem to be parathyroid hor-
mone, FGF-23, or sFRP-4. However, as described
earlier, there is considerable evidence from NaPi-IIb
knockout mice supporting the concept that altera-
tions in intestinalphosphate absorption induce rapid
adaptive changes in renal phosphate handling to
help maintain normal phosphate balance [31,33].
There is evidence that different regions of the
small intestine may play distinct roles in phosphate
homeostasis. In rat, the duodenummay be the locus
of phosphatonin secretion [51], whereas the jeju-
num appears to be the major site of phosphate
absorption and regulation [42,52,53]. Whether
each intestinal region contains unique regulatory
proteins specific to their roles in phosphate absorp-
tion has not been determined. It is, however, inter-
esting to note that the phosphatonins FGF-23 (and
its receptors, FGFR isoforms 1–4) [54] and matrixthorized reproduction of this article is prohibited.
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Klotho [55], are expressed in the small intestine,
although their regional profile has not yet been
examined in any detail. In addition, MEPE [53]
and Klotho [55] are known to influence intestinal
phosphate transport independent of FGF-23 or 1,25
dihydroxyvitamin D3, and may have local direct
effects on phosphate absorption, as well as being
candidates for the circulating enteric phosphatonin.
An interesting new concept is the potential role
of the intestine in the regulation of circulating FGF-
23 levels. The association between chronic hyper-
phosphatemia and FGF-23, and dietary phosphate
intake and FGF-23, is well documented in both
humans and animal models [56,57]. In contrast,
acutemodulation of serum phosphate levels, within
the normal range, by nondietary intervention does
not induce changes in FGF-23 [58,59]. Therefore, it
appears that intestinal phosphate load and/or sens-
ing may be the primary regulator of FGF-23 and that
only supraphysiological changes in serum phos-
phate concentrations are associated with increased
FGF-23 levels. However, how phosphate load is
sensed by the intestine and what signal is respon-
sible for stimulating FGF-23-secreting osteocytes is
unknown and warrants further investigation.CONCLUSION
Tight control of phosphate balance and avoidance
of phosphate overload are now recognized to have
cardiovascular benefits for the general population,
as well as patients with CKD. As increased dietary
phosphate intake through consumption of proc-
essed foods poses a long-term risk to cardiovascular
health, it is crucial to establish the contribution of
different regions of the small intestine to dietary
phosphate absorption, and to determine the mech-
anisms responsible for the interaction between gut
and kidney in maintaining phosphate balance in
health and disease. This information would enable
us to develop more effective ways of manipulating
intestinal phosphate transport to prevent wide
fluctuations in serum phosphate levels, hyperphos-
phatemia, and phosphate overload in CKD.
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